Informations:
Erreur:
ID
13534
Description
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02164578
Lien
https://clinicaltrials.gov/show/NCT02164578
Mots-clés
Versions (1)
- 14/2/16 14/2/16 -
Téléchargé le
14 de febrero de 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Type 2 Diabetic Patients NCT02164578
Eligibility Type 2 Diabetic Patients NCT02164578
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetic Patients NCT02164578
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Type 2 diabetes
Item
Type 2 diabetes duration between 2 and 20 years
boolean
C0011860 (UMLS CUI [1])
Cvd
Item
Documented atherosclerotic cvd:
boolean
C0007222 (UMLS CUI [1])
Cardiovascular event
Item
Major cardiovascular event in medical history
boolean
C1320716 (UMLS CUI [1])
Coronary Stenosis
Item
Coronary angiography showing a coronary artery stenosis of > 50 % or
boolean
C0242231 (UMLS CUI [1])
Carotid Artery Plaque
Item
Carotid ultrasound showing an imt > 1 mm and plaque of carotid artery
boolean
C0751633 (UMLS CUI [1])
Left ventricular hypertrophy
Item
Left ventricular hypertrophy
boolean
C0149721 (UMLS CUI [1])
Macroalbuminuria
Item
Macroalbuminuria in the absence of other renal diseases
boolean
C1654921 (UMLS CUI [1])
High-sensitivity C-reactive protein increased (hscrp)
Item
Increased hscrp (> 2 mg/l but < 10 mg/l) and/or increased pai 1 (> 15 ng/ml)
boolean
C1963867 (UMLS CUI [1])
Statin therapy
Item
Stable treatment with statins (if tolerated)
boolean
C1314135 (UMLS CUI [1])
Age 40 - 75 years
Item
Age 40 - 75 years
boolean
C0001779 (UMLS CUI [1])
Cardiovascular event
Item
CV event with need for oral anticoagulation or dual platelet inhibitor therapy or acute coronary syndrome < 12 month before study entry
boolean
C1320716 (UMLS CUI [1])
Uncontrolled hypertension
Item
Sustained uncontrolled hypertension: systolic bp > 180 mmhg or diastolic bp > 100 mmhg
boolean
C1868885 (UMLS CUI [1])
Hypersensitivity
Item
Hypersensitivity to the active substance
boolean
C0020517 (UMLS CUI [1])
Bleeding
Item
Active clinically significant bleeding
boolean
C0741554 (UMLS CUI [1])
Bleeding Risk
Item
Significant risks for major bleeding
boolean
C3251812 (UMLS CUI [1])
Antiplatelet therapy
Item
Concomitant treatment of acs with antiplatelet therapy in patients with a prior stroke or a transient ischaemic attack (tia)
boolean
C1096021 (UMLS CUI [1])
Hepatic disease
Item
Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
boolean
Chronic renal failure
Item
Chronic renal failure with egfr < 15 ml/min (mdrd formula)
boolean
C0022661 (UMLS CUI [1])
Pregnant or breast-feeding
Item
Pregnant or breast-feeding woman and woman without adequate method of contraception.
boolean
C0549206 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])